IMS Pharmaceutical Pricing & Reimbursement Concise Guide: South Korea

  • ID: 1408495
  • Report
  • Region: South Korea
  • 48 Pages
  • IMS Health
1 of 3

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Note: Product cover images may vary from those shown
2 of 3

1. Healthcare System

  • Facts & Figures
  • Market Indicators
  • Provision & Funding
  • Healthcare Coverage
  • Regulation
  • Provision

2. Pricing

  • Prescription Drugs
  • Price-Volume Agreements
  • New Drugs Developed in South Korea
  • Pricing by Dosage
  • Drugs Subject to Generic Competition
  • Independent Review
  • Ongoing Developments
  • Generic Drugs
  • Pricing Rules
  • Improved New Drugs
  • Regulations Clarifying Pricing for Combination Off-patent Originals/Generics
  • Biosimilars
  • Hospital Drugs
  • Pricing
  • Procurement
  • RSDE
  • OTC Drugs

3. Reimbursement

  • Admission to Reimbursement
  • Procedure
  • Criteria
  • Information Requirements
  • Decision on Maximum Recommended Reimbursement Price
  • Reimbursement Restrictions
  • Combination Drugs
  • Alternative Mechanisms
  • Orphan Drugs/Cancer Treatments
  • Stakeholder/Patient Participation in Decision Making
  • Independent Review
  • Ongoing Developments
  • Reimbursement Categories
  • Reimbursement Prices
  • Hospital Reimbursement
  • Formularies
  • Funding
  • Changes in Reimbursement Status
  • Status Changes
  • HIRA Reviews
  • Reimbursement Review
  • Reclassification of Some ‘Low-cost’ Drugs
  • Punishment for Illegal Rebating
  • Changes in Reimbursement Prices
  • Off-patent Originals
  • Actual Transaction Pricing
  • RSDE
  • Punishments for Illegal Rebates
  • Price-Volume Agreements
  • Expanded Reimbursement
  • Risk-sharing Agreements
  • Products Formerly Classified as Low-cost Drugs
  • Reimbursement Review

4. Pharmacoeconomics

  • Pharmacoeconomic Requirements
  • Guidelines
  • Oncology/Orphan Drugs
  • Ongoing Developments

5. Price Build Up

  • Wholesalers
  • Margins
  • Background
  • Retail Pharmacies
  • Margins
  • Background
  • Dispensing Doctors
  • Sales Tax

6. Cost Containment

  • Industry Paybacks
  • Promotional Costs
  • Patient Co-payments
  • Pharmaceuticals
  • Healthcare
  • Co-payment Ceiling
  • Prescribing Controls
  • Monitoring & Controls
  • Electronic Media
  • High-cost Products
  • Reimbursement Restrictions
  • Incentives
  • Hospital Prescribing Controls
  • Dual Punishment
  • RSDE
  • Generics
  • Market
  • Substitution
  • Generic Prescribing
  • Bioequivalence
  • Patent Linkage
  • Rx-to-OTC Switches
  • Procedure
  • Switches
  • Mass-market OTC
  • OTC Market
  • Parallel Trade

7. Future Developments

  • Outlook
  • Ongoing Consultation on Pricing Reforms
  • New Administration
  • HIRA Reforms
  • Management of Rare Diseases

8. Names & Addresses

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll